Download PDF
Aktuelle Urol 2010; 41: S57-S60
DOI: 10.1055/s-0030-1247237
Review

© Georg Thieme Verlag Stuttgart ˙ New York

Progress in the Management of Advanced Renal Cell Carcinoma (RCC)

T. Q. T. Tong1 , 2 , D. Rohde1 , S. Peter2
  • 1Department of Urology, Academic Hospital Duisburg, Germany
  • 2Department of Urology, Academic Hospital Darmstadt, Germany
Further Information

Publication History

Publication Date:
21 January 2010 (online)

Also available at
    Permissions and Reprints

Abstract

A more profound understanding in the pathophysiological mechanism of renal cell cancer has led to a shift in the treatment approach. Traditionally, cytokines were the frontline drugs, but recently this has transitioned to drugs interacting vascular endothelial growth factor (VEGF) related pathway. Sorafenib, sunitinib, bevacizumab, temsirolimus and everolimus have demonstrated clinical improvements in randomized trials. The purpose of this review is to summarise the current management of advanced RCC.

Key words

renal cell cancer (RCC) - progression free survival (PFS) - Sorafenib - Sunitinib - Bevacizunab - Temsirolimus - Everolimus

References

  • 1 Parkin D M, Bray F, Ferlay J et al. Global cancer statistics 2002 CA Cancer.  J Clin. 2005;  55 74-108
    Google Scholar
  • 2 Lam R S, Leppert J T, Belldegrum A S et al. Novel approaches in the therapy of metastatic renal cell carcinoma.  World J Urol. 2005;  23 202-212
    CrossrefPubMedGoogle Scholar
  • 3 Janzen N K, Kim H L, Figlin R A et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.  Urol Clin North Am. 2003;  30 843-852
    CrossrefPubMedGoogle Scholar
  • 4 Fisher R I, Rosenberg S A, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.  Cancer J Sci Am. 2000;  6 Suppl 1 55-57
    PubMedGoogle Scholar
  • 5 Motzer R J, Michaelson M D, Redman B G et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.  J Clin Oncol. 2006;  24 16-24
    CrossrefPubMedGoogle Scholar
  • 6 Motzer R J, Rini B I, Bukowski R M et al. Sunitinib in patients with metastatic renal cell carcinoma.  JAMA. 2006;  295 2516-2524
    CrossrefPubMedGoogle Scholar
  • 7 Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal cell carcinoma: 1983–1993.  Semin Oncol. 1995;  22 42-60
    PubMedGoogle Scholar
  • 8 McDermott D F, Atkins M B. Application of IL-2 and other cytokines in renal cancer.  Expert Opin Biol Ther. 2004;  4 455-468
    CrossrefPubMedGoogle Scholar
  • 9 Hutson T E, Quinn D I. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?.  Clin Genitourin Cancer. 2005;  4 181-186
    CrossrefPubMedGoogle Scholar
  • 10 Folkman J. Tumor angiogenesis: therapeutic implications.  N Engl J Med. 1971;  285 1182-1186
    CrossrefPubMedGoogle Scholar
  • 11 Clifford S C, Prowse A H, Affara N A et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.  Genes Chromosomes Cancer. 1998;  22 200-209
    CrossrefPubMedGoogle Scholar
  • 12 Herman J G, Latif F, Weng Y et al. Silencing of the VHL tumorsuppressor gene by DNA methylation in renal carcinoma.  Proc Natl Acad Sci USA. 1994;  91 9700-9704
    CrossrefPubMedGoogle Scholar
  • 13 Kibel A, Iliopoulos O, DeCaprio J A et al. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.  Science. 1995;  269 1444-1446
    CrossrefPubMedGoogle Scholar
  • 14 Krieg M, Haas R, Brauch H et al. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.  Oncogene. 2000;  19 5435-5443
    CrossrefPubMedGoogle Scholar
  • 15 Gnarra J R, Zhou S, Merrill M J et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.  Proc Natl Acad Sci USA. 1996;  93 10589-10594
    CrossrefPubMedGoogle Scholar
  • 16 de Paulsen N, Brychzy A, Fournier M C et al. Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)- / - clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis.  Proc Natl Acad Sci USA. 2001;  98 1387-1392
    CrossrefPubMedGoogle Scholar
  • 17 Motzer R J, Hutson T E, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.  N Engl J Med. 2007;  356 115-124
    CrossrefPubMedGoogle Scholar
  • 18 Escudier B, Eisen T, Stadler W M et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.  J Clin Oncol. 2009;  27 3312-3318
    CrossrefPubMedGoogle Scholar
  • 19 Yang J C, Haworth L, Sherry R M et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.  N Engl J Med. 2003;  349 427-434
    CrossrefPubMedGoogle Scholar
  • 20 Bukowski R M, Kabbinavar F, Figlin R A et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). In 2006 ASCO Annual Meeting Proceedings.  J Clin Oncol. 2006;  24 4523
    CrossrefPubMedGoogle Scholar
  • 21 Kaufman J J. Cancer of the urogenital tract: kidney. Reasons for nephrectomy: palliative and curative.  JAMA. 1968;  204 607-608
    CrossrefPubMedGoogle Scholar
  • 22 Wood C G. The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma.  Urol Clin North Am. 2003;  30 581-588
    CrossrefPubMedGoogle Scholar
  • 23 Wilhelm S M, Carter C, Tang L et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF / MEK / ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.  Cancer Res. 2004;  64 7099-7109
    CrossrefPubMedGoogle Scholar
  • 24 Clark J W, Eder J P, Ryan D et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43–9006, in patients with advanced, refractory solid tumors.  Clin Cancer Res. 2005;  11 5472-5480
    CrossrefPubMedGoogle Scholar
  • 25 Ratain M J, Eisen T, Stadler W M et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.  J Clin Oncol. 2006;  24 2505-2512
    CrossrefPubMedGoogle Scholar
  • 26 Escudier B, Eisen T, Walter M et al. Sorafenipb in advanced clear-cell renal-cell carcinoma.  N Engl J Med. 2007;  356 125-134
    CrossrefPubMedGoogle Scholar
  • 27 Gollob J, Rathmell W K, Richmond T M et al. Phase II trial of sorafenib plus interferon-alpha 2b (IFN-α2b) as first- or second-line therapy in patients with metastatic renal cell cancer (RCC).   J Clin Oncol. 2007;  25 3288-3295
    CrossrefPubMedGoogle Scholar
  • 28 Chow L Q, Eckhardt S G. Sunitinib: from rational design to clinical efficacy.   J Clin Oncol. 2007;  25 884-896
    CrossrefPubMedGoogle Scholar
  • 29 Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.   J Clin Oncol. 2007;  24 25-35
    CrossrefPubMedGoogle Scholar
  • 30 De Mulder P H, Roigas J, Gillessen S et al. A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokinerefractory metastatic renal cell carcinoma (mRCC).   J Clin Oncol. 2006;  24 (suppl) 4529
    PubMedGoogle Scholar
  • 31 Rini B I, George D J, Michaelson M D et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC).  J Clin Oncol. 2006;  24 (suppl) 4522
    PubMedGoogle Scholar
  • 32 Dudkin L, Dilling M B, Cheshire P J et al. Biochemical Correlates of mTOR Inhibition by the Rapamycin Ester CCI-779 and Tumor Growth Inhibition.  Clin Cancer Res. 2001;  7 1758-1764
    PubMedGoogle Scholar
  • 33 Hudson C C, Liu M, Chiang G G et al. Regulation of Hypoxia-Inducible Factor 1_ Expression and Function by the Mammalian Target of Rapamycin.   Moll Cell Biol. 2002;  22 7004-7014
    CrossrefPubMedGoogle Scholar
  • 34 Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.   N Engl J Med. 2007;  356 2271-2281
    CrossrefPubMedGoogle Scholar
  • 35 Gore M E, Porta C, Oudard S et al. Sunitinib in metastatic renal cell carcinoma.   Pro ASCO. 2007;  Abstract 5010
    PubMedGoogle Scholar
  • 36 Motzer R J, Hutson T E, Tomezak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.   J Clin Oncol. 2009;  27 3584-3590
    CrossrefPubMedGoogle Scholar
  • 37 Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alpha-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.   Lancet. 2007;  370 2103-2111
    CrossrefPubMedGoogle Scholar
  • 38 Amato R J, Jac J, Giessinger S et al. A phase 2 study with a daily regime of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.   Cancer. 2009;  115 2438-2446
    CrossrefPubMedGoogle Scholar
  • 39 Motzer R J, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double blind, randomised, placebo-controlled phase III trial.   Lancet. 2008;  372 449-456
    CrossrefPubMedGoogle Scholar

T. Q. T. Tong

Department of Urology,Academic Hospital Duisburg

Wanheimerstraße 167 a

47053 Duisburg

Germany

Phone: +49 / 2 03 / 6 00 90

Email: tqttong@gmail.com

      >